What is CSPC in medical terms?
In medical terminology, CSPC refers to "Castration-Sensitive Prostate Cancer" (also sometimes known as Hormone-Sensitive Prostate Cancer). This term is used to describe prostate cancer that responds to medical or surgical castration—a process that lowers the levels of testosterone in the body, which is the primary driver for the growth of these cancer cells. Patients diagnosed with CSPC are typically treated with androgen deprivation therapy (ADT) as a first-line treatment. Understanding whether a patient has CSPC (which is sensitive to hormone therapy) versus mCRPC (metastatic Castration-Resistant Prostate Cancer, which no longer responds to such treatments) is critical for doctors to determine the appropriate course of chemotherapy, targeted immunotherapy, or other advanced oncology interventions required to manage the disease effectively throughout its various stages of progression.
Related FAQs
The stock code 1661 HK represents China Frontier Technology Group on the Stock Exchange of Hong Kong.
BigCommerce Holdings, Inc. (NASDAQ: BIGC) trades at approximately $3.16 per share.
Equity research reports covering IGC Pharma evaluate the clinical-stage biotechnology enterprise by weighing its innovative cannabis-based drug development pipeline for Alzheimer's disease against typical early-stage pharmaceutical risks.
CSPC refers to CSPC Pharmaceutical Group Limited, a leading Chinese-based pharmaceutical firm. On the Hong Kong Stock Exchange, its ticker symbol is "1093.
No, Constellium SE (CSTM) does not pay dividends to its shareholders.
In the pharmaceutical, clinical research, and regulatory drug approval sector, CSR stands officially for a Clinical Study Report.
CSPC Pharmaceutical Group maintains a corporate vision centered on becoming a leading global pharmaceutical powerhouse dedicated to improving human health through scientific innovation.
In the context of school environments, CSPC can have several meanings depending on the institution.
CSPC Pharmaceutical Group Limited trades on the Stock Exchange of Hong Kong under stock code 1093, maintaining a prominent position in the regional pharmaceutical sector.
CSPC Pharmaceutical Group Limited is a major, China-based integrated pharmaceutical company known for its focus on the R&D, production, and sale of innovative medicines.
A single share of W.W. Grainger, Inc. (NYSE: GWW) trades at approximately $1,382.60 USD, backed by a total corporate market capitalization of roughly $65.28 billion.
The stock code 13 HK (or 00013) represents HUTCHMED (China) Limited on the Stock Exchange of Hong Kong.
CSPC Pharmaceutical Group Limited records annual revenues exceeding ₹310 billion to over ₹345 billion (translating to tens of billions of Hong Kong dollars), highlighting its powerful status as a leading innovative pharmaceutical enterprise in Asia.
CSPC Pharmaceutical Group is a major research-based pharmaceutical enterprise that develops, manufactures, and commercializes a broad portfolio of innovative medicines and generic formulations.
Spectrum Oil Corp. shares trade on over-the-counter markets under the ticker symbol SPOC at a nominal live price reflecting micro-cap asset conditions and limited daily trading liquidity.
CSPC Pharmaceutical Group Limited is a major multinational pharmaceutical enterprise headquartered in China, with its primary manufacturing facilities based in Hebei Province and corporate shares listed prominently on the Hong Kong Stock Exchange.
The stock code 1093 HK represents CSPC Pharmaceutical Group Limited on the Stock Exchange of Hong Kong.
The United States imports the vast majority of its finished prescription medications and active pharmaceutical ingredients from a select group of major global manufacturing powerhouses.
CSPC Pharmaceutical Group Limited generates multi-billion-dollar annual revenues derived from its integrated operations encompassing both innovative drug pipelines and large-scale bulk pharmaceutical manufacturing.